Roujeinikova A, Modak J, Pike R and Drag M
Monash University, Australia
Wroclaw University of Technology, Poland
Posters & Accepted Abstracts: Med chem
The standard H. pylori eradication therapy has lost its efficacy, with an eradication rate dropping to as low as 60% in Western Europe. Aiming to develop an alternative therapy, we have performed initial characterisation of H. pylori M17 aminopeptidase (HpM17AP). To address the structural basis of catalysis and inhibition of this enzyme, we have established its specificity towards an N-terminal amino acid of the substrate and determined the crystal structures of HpM17AP and its complex with the inhibitor bestatin. We have analysed the diffraction data sets for HpM17AP and its bestatin complex. HpM17AP activity was screened against a fluorogenic substrate library containing both natural and unnatural amino acids. The position of phenylalanine moiety of the inhibitor with respect to the active-site residues and with respect to other M17 aminopeptidases suggested that it represents the S1 subsite. In contrast to most characterized M17 aminopeptidases, HpM17AP displays preference to L-Arg over L-Leu. A close similarity between the structures of HpM17AP and its homologues from other bacteria has allowed the structural features that determine differences in their substrate specificity to be analysed. The results have interesting implications for metabolic utilisaton of arginine for the production of primary amines, and cysteine scavenging through degradation of mucosal glutathione.
Email: anna.roujeinikova@monash.edu
Medicinal Chemistry received 6627 citations as per Google Scholar report